新发心房颤动

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.

• 全文
• 摘要

Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467-2477.

• 全文
• 摘要

Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478-2486.

• 全文
• 摘要

O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012;34:894-901.

• 摘要

Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-460.

• 摘要

National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. March 2012. http://www.nice.org.uk (last accessed 8 January 2016).

• 全文

1.  Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:e269-e367.

• 全文
• 摘要

2.  January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1-e76.

• 全文
• 摘要

3.  Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609-1678.

• 全文
• 摘要

4.  Prystowsky EN, Benson DW Jr, Fuster V, et al. Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93(6):1262-77.

• 全文
• 摘要

5.  Falk RH. Atrial fibrillation. N Engl J Med. 2001;344:1067-1078.

• 摘要

6.  Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998;352:1167-1171.

• 摘要

7.  Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997;47:285-289.

• 全文
• 摘要

8.  Lip GY, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J. 1994;71:92-95.

• 全文
• 摘要

9.  Zarifis J, Beevers G, Lip GY. Acute admissions with atrial fibrillation in a British multiracial hospital population. Br J Clin Pract. 1997;51:91-96.

• 摘要

10.  National Institute for Health and Care Excellence. Atrial fibrillation: management. 2014. https://www.nice.org.uk/guidance/cg180 (last accessed 8 January 2016).

• 全文

11.  Lip GYH, Apostolakis S. Atrial fibrillation (acute onset). BMJ Clin Evid. November 2014. http://clinicalevidence.bmj.com/ (last accessed 8 January 2016).

• 全文

12.  Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke, results from a population-based study. Stroke. 2005;36:1115-1119.

• 摘要

13.  Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemostat. 2005;3:1218-1223.

• 摘要

14.  Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014;370:2467-2477.

• 全文
• 摘要

15.  Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478-2486.

• 全文
• 摘要

16.  Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J. 2000;140;878-885.

• 摘要

17.  Asanin M, Perunicic J, Mrdovic I, et al. Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. Eur J Heart Failure. 2005;7:671-676.

• 摘要

18.  Mentz RJ, Chung MJ, Gheorghiade M, et al. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Am Heart J. 2012;164:884-892.e2.

• 全文
• 摘要

19.  Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women. Circulation. 2005;112:1736-1742.

• 全文
• 摘要

20.  Agarwal A, York M, Kantharia BK, et al. Atrial fibrillation: modern concepts and management. Annu Rev Med. 2005;56:475-494.

• 摘要

21.  Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66.

• 全文

22.  Peters NS, Schilling RJ, Kanagaratnam P, et al. Atrial fibrillation: strategies to control, combat, and cure. Lancet. 2002; 359;593-603.

• 摘要

23.  Kochiadakis GE, Skalidis EI, Kalebubas MD, et al. Effect of acute atrial fibrillation on phasic coronary blood flow pattern and flow reserve in humans. Eur Heart J. 2002;23:734-741.

• 摘要

24.  Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study. JAMA. 1994;271:840-844.

25.  Lip GY, Beevers DG, Singh SP, et al. ABC of atrial fibrillation. Aetiology, pathophysiology, and clinical features. BMJ. 1995;311:1425-1428.

• 全文
• 摘要

26.  Hijazi Z, Siegbahn A, Andersson U, et al. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625-634.

• 全文
• 摘要

27.  Fauchier L, Clementy N, Pelade C, et al. Patients with ischemic stroke and incident atrial fibrillation: a nationwide cohort study. Stroke. 2015;46:2432-2437.

• 全文
• 摘要

28.  Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.

• 全文
• 摘要

29.  Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy). Am J Cardiol. 2012;110:222-226.

• 摘要

30.  Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-719.

• 摘要

31.  Saliba W, Gronich N, Barnett-Griness O, et al. Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study. Am J Med. 2016;129:843-849.

• 摘要

32.  Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.

• 摘要

33.  Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol. 2002;13:542-547.

• 摘要

34.  Kanji S, Stewart R, Fergusson DA, et al. Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized controlled trials. Crit Care Med. 2008;36:1620-1624.

• 摘要

35.  Okcun B, Yigit Z, Yildiz A, et al. What should be the primary treatment in atrial fibrillation: ventricular rate control or sinus rhythm control with long-term anticoagulation? J Int Med Res. 2009;37:464-471.

• 摘要

36.  Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151 (erratum in: N Engl J Med. 2010;363:1877).

• 全文
• 摘要

37.  Singh BN, Connolly SJ, Crijns HJ, et al; EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999.

• 全文
• 摘要

38.  Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.

• 摘要

39.  Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678 (erratum in: N Engl J Med. 2009;360:2487).

• 摘要

40.  National Institute for Health and Care Excellence. Dronedarone for the treatment of non-permanent atrial fibrillation. August 2010. http://www.nice.org.uk (last accessed 8 January 2016).

• 全文

41.  National Institute for Health and Care Excellence. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation. May 2012. http://www.nice.org.uk (last accessed 8 January 2016).

• 全文

42.  O'Dell KM, Igawa D, Hsin J. New oral anticoagulants for atrial fibrillation: a review of clinical trials. Clin Ther. 2012;34:894-901.

• 摘要

43.  Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-460.

• 摘要

44.  National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation. March 2012. http://www.nice.org.uk (last accessed 8 January 2016).

• 全文

45.  Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.

• 全文
• 摘要

46.  Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

• 全文
• 摘要

47.  Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.

• 全文
• 摘要

48.  Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388:1995-2003.

• 摘要

49.  Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015;101:1204-1211.

• 摘要

50.  Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014;127:1083-1088.

• 摘要

51.  Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014;146:719-726.

• 全文
• 摘要

52.  Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009;54:1089-1095.

• 摘要

53.  Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic review. Scand Cardiovasc J Suppl. 2013;47:2-10.

• 摘要

54.  Roy D, Pratt CM, Torp-Pedersen C, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518-1525.

• 全文
• 摘要

55.  Kowey PR, Dorian P, Mitchell LB, et al; Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652-659.

• 全文
• 摘要

56.  Camm AJ, Capucci A, Hohnloser SH, et al; AVRO Investigators. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-321.

• 摘要

57.  Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. A comparative study of the efficacy and safety of procainamide versus propafenone versus amiodarone for the conversion of recent-onset atrial fibrillation. Am J Cardiol. 2007;99:1721-1725.

• 摘要

58.  Xanthos T, Bassiakou E, Vlachos IS, et al. Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. Int J Cardiol. 2007;121:291-295.

• 摘要

59.  Xanthos T, Prapa V, Papadimitriou D, et al. Comparative study of intravenous amiodarone and procainamide in the treatment of atrial fibrillation of recent onset. Minerva Cardioangiol. 2007;55:433-441.

• 摘要

60.  Torp-Pedersen C, Raev DH, Dickinson G, et al. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion. Circ Arrhythm Electrophysiol. 2011;4:637-643.

• 全文
• 摘要

61.  Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-2391.

• 全文
• 摘要

62.  Sorino M, Colonna P, De Luca L, et al. Post-cardioversion transesophageal echocardiography (POSTEC) strategy with the use of enoxaparin for brief anticoagulation in atrial fibrillation patients: the multicenter POSTEC trial (a pilot study). J Cardiovasc Med (Hagerstown). 2007;8:1034-1042.

• 摘要

63.  Grönberg T, Hartikainen JE, Nuotio I, et al. Anticoagulation, CHA2DS2VASc score, and thromboembolic risk of cardioversion of acute atrial fibrillation (from the FinCV study). Am J Cardiol. 2016;117:1294-1298.

• 摘要

64.  Lip GY, Skjøth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015;65:1385-1394.

• 摘要

65.  Chao TF, Liu CJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol. 2015;65:635-642.

• 摘要

66.  Joundi RA, Cipriano LE, Sposato LA, et al. Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis. Stroke. 2016;47:1364-1367.

• 摘要

67.  Miller MR, McNamara RL, Segal JB, et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract. 2000;49:1033-46.

• 全文
• 摘要

68.  sanofi-aventis. Important information on the use of Multaq® (dronedarone). June 2009. http://www.accessdata.fda.gov/ (last accessed 8 January 2016).

• 全文

69.  Kober L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687 (erratum in: N Engl J Med. 2010;363:1384).

• 全文
• 摘要

70.  Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011;123:1587-1593.

• 全文
• 摘要

71.  Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013;310:2050-2060.

• 全文
• 摘要